Sinecatechins

DB01266ApprovedInvestigationalNutraceuticalSmall molecule

Sinecatechins is a topical agent used to treat external genital and perianal warts in immunocompetent adult patients. Sinecatechins is a botanical drug product for topical use.

Mechanism: While the exact mechanism of action of catechins is unknown, they are powerful anti-oxidants and are linked to to evidence of fighting tumors as well as enhancing immune system function.
Curator reviewed
Primary indication: For the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.Curator reviewed · 2 structured indications
First approval: Canada, 2026 · United States, 2007
Also known as: CAMELLIA SINENSIS LEAF CATECHINS · Kunecatechins · Polyphenon E
Brand names: Veregen

Resolves to

Compound

UNIIT432289GYZCAS188265-33-0

Clinical / RWD

RxNorm753346ATCD06BB12PharmGKBPA164749508

Targets

P23219PTGS1P14780MMP9P35354PTGS2P08253MMP2P00533EGFRP09237MMP7Q9NYA1SPHK1

What you can answer from here — as of July 17, 2026

8Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

27Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

4Marketed productsAcross 3 countries and 4 labellers

1ATC codeIncluding every combination product, plus 8 drug categories

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sinecatechins, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In